Leave us a message
We are ready to answer you as soon as possible!
I consent to the processing of personal data and agree to the user agreement and privacy policy.
Back to products
C+E Max
Original price was: S/350.00.S/300.00Current price is: S/300.00.
Cellular Matrix A-CP-HA
Cellular Matrix® tubes allow the preparation of autologous platelet-rich plasma (RegenPRP®) combined with non-cross-linked hyaluronic acid (HA) in a closed-loop system.
CM-PRP-HA has an excellent safety profile in clinical practice.
Cellular Matrix® technology combines the complementary clinical effects of RegenPRP® and hyaluronic acid (HA), providing better, longer-lasting results in patients with osteoarthritis.
Hyaluronic acid
- Hyaluronic acid is an important component of synovial fluid that contributes to joint homeostasis.
- 25 years of clinical experience shows pain relief and functional improvement lasting 6 to 12 months in patients with OA.
- It plays an important role in viscosupplementation and pain relief in OA.
- The network of HA chains generates an ideal matrix for cells when combined with PRP.
- Hyaluronic acid enhances the activity of several molecules contained in platelet-rich plasma to provide additional benefits to OA patients.
Description
Both PRP and HA have been widely used to improve lubrication, modulate inflammation, and modify the joint catabolic microenvironment, with the goal of not only reducing clinical symptoms but also slowing the progression of OA.
When PRP and HA are used in combination, these effects are increased and prolonged. HA creates a bioactive scaffold on which platelets progressively release their growth factors. RegenPRP does not negatively affect the mechanical, elastic or viscous properties of HA.
ADVANTAGES OF THE TECHNOLOGY
- Standardized user-independent preparation.
- Minimum blood volume required.
- Secure closed loop system.
- Mechanical isolation of PRP using a biologically inert gel after a 5-minute centrifugation.
- Reversible anticoagulation with a pharmaceutical grade sodium citrate solution at pH 7.
- Minimal learning curve and ease of use.
- Operationally and clinically efficient process.
- Facilitates and speeds up routine practice.
CELLULAR MATRIX PLATFORM
- Certified technology for the preparation of RegenPRP® combined with hyaluronic acid (HA) (CM-PRP-HA).
- Contains 2 ml of non-cross-linked HA at a concentration of 20 mg/ml (40 mg total).
- HA is produced by bacterial fermentation, so it does not contain animal proteins.
SCIENTIFIC ADVANTAGES OF REGENPRP®
- Proven safety and effectiveness.
- Evidence-based results for numerous therapeutic indications.
- Large number of clinical studies, with more than 200 publications.
BIOLOGICAL ADVANTAGES
- RegenPRP® is standardized, reduced in leukocytes and easily reproducible.
- Regen Lab’s specific separating gel technology ensures minimal variability.
- Platelet recovery in CM-PRP-HA >70%.
- High platelet quality.
- Viable and functional platelets.
- Complete plasma recovery.
- Without loss of plasma growth factors and fibrinogen.
- Reduced leukocytes PRP Depletion ~94.3% of pro-inflammatory granulocytes, leaving mainly lymphocytes and monocytes.
- There are practically no red blood cells.
- Depletion of ~99.5% of erythrocytes.
Related products
ArthroVisc 40
ArthroVisc®40 is a non-cross-linked hyaluronic acid (2 %) obtained from bacterial fermentation.
This product is sterile and non-pyrogenic.
It is packaged in 2 ml syringes of hyaluronic acid ( 20 mg/ml, 1500 KDa).
ArthroVisc®40 is available in three syringes of 2 ml. It is for single use and designed to be used with sterile needles (25G or 27G), not supplied in the kit.
Composition :
2 mL of solution contains 40mg of hyaluronic acid in phosphate buffer (Sodium chloride, Dipotassium hydrogenphosphate, Potassium dihydrogenphosphate, Potassium chloride) and water for injection.
